Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older Medically Infirm or Frail Patients With Blood Diseases

  • STATUS
    Recruiting
  • End date
    Jun 30, 2025
  • participants needed
    600
  • sponsor
    Fred Hutchinson Cancer Research Center
Updated on 21 September 2021
cancer
blood disorder
cell transplantation
hematologic disorders

Summary

This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.

Description

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I: Patients undergo SPC on days -15 before to +56 after transplant.

ARM II: Patients undergo a CMC program on days -15 before to +56 after transplant.

ARM III: Patients undergo interventions as outlined in Arm I and Arm II.

ARM IV: Patients receive standard of care.

In all arms, patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment and 30, 90, 180, and 365 days post HCT. In all arms patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.

Details
Condition Hematologic Malignancy, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic malignancy, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder, Non-Neoplastic Hematologic and Lymphocytic Disorder
Treatment questionnaire administration, quality-of-life assessment, allogeneic hematopoietic stem cell transplantation, survey administration, Best Practice, clinical management, Supportive Palliative Care
Clinical Study IdentifierNCT03870750
SponsorFred Hutchinson Cancer Research Center
Last Modified on21 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Vulnerable patients as defined by one or more of the following criteria
Age 65 years or older
Having Hematopoietic Cell Transplantation - Comorbidity Index (HCT-CI) scores of >= 3 (for patients that could be 20 years old and older)
Having frailty as determined by walk speed of < 0.8 m/s using 4-meter walk test (for patients that could be 40 years old and older)
Patients considered or referred for allogeneic HCT to treat a hematological malignant or non-malignant disease
Able to speak and read English - interaction with the interventionist trainer and endpoint measurement must occur in English
Willing and able to provide informed consent
Planned allogeneic HCT within 3 weeks - all types of donors and all sorts of conditioning regimens are allowed. Patients with suspected active disease (relatively old disease staging or relatively old intervention) or significant comorbidity (e.g. suspicious untreated pulmonary nodules) based on prior evaluations, that could delay the transplant would be considered for enrollment within a tighter window (10-14 days before allogeneic HCT) to allow for completed pre-HCT work-up evaluations that would confirm readiness to proceed with transplant
Able to exercise at low to moderate intensity, specifically taking into consideration the rare circumstances where subjects are not able to exercise due to either birth deformity or prior traumatic injury that affects their gait
Adequate cardiopulmonary reserve, as judged by data from the patient's electronic medical record as to whether a patient could walk up one flight of stairs, no need for supplemental oxygen, and/or physician judgment

Exclusion Criteria

Orthopedic, neurologic or other problems which prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility
Participation in another intervention clinical trial with HRQOL as a primary endpoint
Planned donor lymphocyte infusion (DLI) within 90 days post-transplant
Planned anti-cytotoxic therapies, other than tyrosine kinase inhibitors or single-agent monoclonal antibody, or FLT-3 inhibitors within 90 days of post-transplant unless pre-approved by the protocol principal investigator (PI)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note